Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

Investigators at the Jacobs School of Medicine and Biomedical Sciences have uncovered how heat causes a critical receptor protein within cells to unfold and relay pain, which could open up new ...

A new study shows that enhancing activity of a specific component of 'NMDA' receptors normalizes protein synthesis, neural activity and seizure susceptibility in the hippocampus of fragile X lab mice.

A study of depressed individuals found that an eight‐week treatment with selective serotonin reuptake inhibitors (SSRIs) ...

Striatal dopamine (DA) release regulates reward-related learning and behavioural activation and is believed to consist of a short-lived phasic and continuous tonic component. Here, we build a ...

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 ...

This study presents solid evidence for distinct neurotransmitter release modalities between two subclasses of dopaminergic neurons in the olfactory bulb, highlighting an important finding that ...

In preliminary studies, we discovered that selected typical and atypical antipsychotic drugs interacted with virtually every biogenic amine receptor tested, in confirmation of many prior studies ...

The White House on Tuesday justified a sweeping freeze in US overseas assistance by citing a $50 million condom distribution program in the Gaza Strip, without offering evidence to back up the claim.

A study showed that changes in the functioning of opioid neurotransmitters in the brain may underlie anorexia. A study conducted at Turku PET Centre in Finland showed that changes in the ...